Cogstate Ltd

The Business

Cogstate designs and delivers computerised cognitive assessments used as primary or secondary endpoints in central nervous system clinical trials, spanning Alzheimer's disease, psychiatric disorders, sleep and rare neurological conditions. Pharmaceutical sponsors licence its testing platform and rely on its scientific validation to satisfy regulators that a drug's cognitive benefit is real. The business is asset-light: revenue comes from per-trial and per-patient fees rather than manufacturing or property, and gross margins sit near 58-60%. Around 171 trials currently run on Cogstate's platform, with an estimated 25-30% share of the CNS cognitive endpoint niche.

Recent Performance

Cogstate's FY26 result was its strongest on record. New contract wins reached A$89 million, up 116% on the prior year's already-elevated base. Revenue reached US$60.9 million, EBITDA margins held near 30%, and the balance sheet carries zero debt against US$34.8 million of net cash. The market has rewarded this with a sustained re-rating; the stock now trades around 14.7 times forward EBITDA, above its own three-year average and at the upper end of clinical-trial services peers.

Outlook

Revenue growth is expected to decelerate over the coming years as the FY26 contract surge normalises against a much larger base, though the pace of that deceleration is a key input to how the business is valued. EBITDA margins are expected to hold broadly steady, supported by diversification into seven non-Alzheimer's therapeutic areas that now account for 77% of new contracts. Earnings are forecast to grow at a steadier pace than the lumpy contract-win data suggests on its own, as a multi-year pipeline of trials already on the platform converts through to revenue regardless of new signings.

Key Risks

Eli Lilly generates 42% of Cogstate's revenue, and any reduction in that relationship, whether partial or a full exit, represents the single largest customer-specific exposure in the business. A biotech funding downturn is a second risk to watch: the NASDAQ Biotech Index sits near a multi-year high, and a reversal could materially slow new clinical trial starts industry-wide. Third, the record A$89 million contract year in FY26 may not repeat; Cogstate's revenue has been lumpy before, including a 14% decline in FY23, and a normalisation back toward historical contract-win levels would meaningfully change the growth trajectory the current price appears to assume.

What to Watch

The thesis-defining event is Cogstate's first-half FY27 result in February 2027, which will show whether contract wins are normalising and whether Lilly's revenue share is still rising.

• February 2027 1H FY27 results: tests whether contract wins are normalising and whether Lilly's revenue share is falling.
• August 2027 FY27 full-year results: the definitive test of whether the FY26 surge was structural or cyclical.

Company Description

Cogstate operates as a single-segment contract research organisation specialising in cognitive testing for central nervous system clinical trials. The core Clinical Trials division, generating US$58.4 million of FY26 revenue, licenses computerised cognitive assessment batteries to pharmaceutical sponsors running trials in Alzheimer's disease, psychiatric disorders, sleep and rare neurological conditions. A smaller Healthcare division (US$2.5 million, in gradual decline) provides cognitive testing tools outside the clinical trial setting. Cogstate does not manufacture drugs or run trial sites; it supplies the standardised, regulator-accepted measurement tool sponsors need to prove a treatment works on cognition, then charges per-trial and per-patient fees across the life of each study, typically two to five years.

Where the Growth Is

The largest driver of Cogstate's growth is diversification beyond Alzheimer's disease. As recently as a few years ago, more than half of contracts were Alzheimer's-dependent; in FY26, 77% of new contracts came from seven other therapeutic areas, including psychiatry, sleep disorders and rare disease. This has structurally expanded Cogstate's addressable market from roughly US$1 billion in Alzheimer's-only trials to an estimated US$2-3 billion across broader CNS indications. The shift is observable in contract data, not just management commentary, and it reduces dependence on the fortunes of any single disease category or drug programme.

Competitive Position

Cogstate's advantage rests on a 25-year library of scientific validation: its cognitive assessments are accepted by the FDA and EMA as primary or secondary endpoints in registrational trials, a status that took decades of published studies to earn. A rival attempting to replicate this would need years of clinical data and regulatory acceptance before it could compete on equal footing, which is why competitive intensity in this niche has stayed low even as the addressable market has grown. Cogstate holds an estimated 25-30% share of the CNS cognitive endpoint market, and that position is widening as diversification opens new therapeutic areas where its validation library already applies. Switching costs reinforce the position at the trial level: once a sponsor selects Cogstate's endpoint for a study, changing providers mid-trial would invalidate the scientific comparability of results, locking in revenue for the life of each contract.

Management & Capital Discipline

Management has delivered on its two stated priorities: diversifying away from Alzheimer's dependence and holding EBITDA margins near 30%. Capital allocation in FY26 returned A$5.2 million to shareholders via buybacks and a maiden dividend, against US$11.9 million of net profit, while still funding a US$10-12 million investment in an AI-enabled testing platform over FY27-28. That balance of growth investment and shareholder returns suits a business generating a 30% return on invested capital. The honest caveat is that insider ownership disclosure is limited and the leadership team is small, which creates key-person risk that is not fully visible from public filings.

Financial Position

Cogstate carries zero debt and US$34.8 million of net cash against a market capitalisation of roughly A$452 million. Its current ratio, a measure of short-term liquidity, sits near 3.5 times, and net cash alone could fund the business through a 30% revenue decline for well over two years without external capital. This gives Cogstate genuine flexibility to keep investing in its AI platform, sustain its new dividend, and absorb a downturn in trial starts without financial stress, even though revenue is inherently lumpy given the project-based nature of clinical trial contracts.